2825 Airview Blvd
Portage, Michigan 49002-1802
Phone: 12693892600
www.stryker.com
In the current session, the stock is trading at $351.79, after a 0.63% spike. Over the past month, Stryker Inc. (NYSE: SYK ) stock increased by 1.24% , and in the past year, by 26.87% . With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued. How Does Stryker P/E Compare to Other Companies? The P/E ratio is used by long-term shareholders to assess the company''s market performance against … Full story available on Benzinga.com
New system streamlines workflows and enhances usability Stryker (NYSE:SYK), a global leader in medical technologies, today announced the release of its Gamma4 Hip Fracture Nailing System in most o…
Stryker (NYSE: SYK ) has outperformed the market over the past 20 years by 2.91% on an annualized basis producing an average annual return of 10.81%. Currently, Stryker has a market capitalization of $134.09 billion. Buying $100 In SYK: If an … Full story available on Benzinga.com
https://www.investing.com/news/stock-market-news/stryker-finalizes-acquisition-of-french-joint-replacement-firm-93CH-3347789
Stryker (SYK) completes the acquisition of SERF SAS, a joint replacement company, from Menix, enhancing its global portfolio and orthopaedic excellence. SERF SAS brings over 50 years of innovation in hip implants, strengthening Stryker''s presence in France, Europe, and globally.
MAHWAH, N.J., USA, March 21, 2024 /PRNewswire/ -- Stryker (NYSE: SYK), a leading global medical technology company, announced today that it has completed the previously announced acquisition of SERF SAS, a France-based joint replacement company, from Menix. "The acquisition of SERF SAS…
In a recent report, global wealth manager UBS identified the sectors likely to drive the next wave of technological innovation and the stocks that stand to benefit. What Happened: UBS has pinpointed artificial intelligence (AI), cybersecurity, health tech, Greentech, and fintech as the sectors that will produce the “next big thing” in tech. The bank has selected 29 companies that are expected to experience “superior” earnings growth compared to the market, driven by “positive, durable structural trends,” CNBC reported on Sunday. "Collectively, we see industry leaders for 2030 emerging from these sectors," said UBS in a March 14 report. Among the companies on UBS’ list are: McKesson Corp (NYSE: MCK ): The company’s expansion into data-driven services across the U.S. healthcare value chain will cause UBS to be bullish in the future. Baidu (NASDAQ: BIDU ): UBS sees Baidu’s expertise in AI and machine learning, particularly in its non-advertising businesses like autonomous driving and cloud, as potential long-term growth drivers.
High-rolling investors have positioned themselves bearish on Stryker (NYSE: SYK ), and it''s important for retail traders to take note. \This activity came to our attention today through Benzinga''s tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in SYK often signals that someone has privileged information. Today, Benzinga''s options scanner spotted 10 options trades for Stryker. This is not a typical pattern. The sentiment among these major traders is split, with 40% bullish and 60% bearish. Among all the options we identified, there was one put, amounting to $39,000, and 9 calls, totaling $557,142. What''s The Price Target? After evaluating the trading volumes and Open Interest, it''s evident that the major market movers are focusing on a price band between $300.0 and $370.0 for Stryker, spanning the last three months. Insights into Volume & Open Interest Assessing the volume and … Full story available on Benzinga.
Stryker (NYSE: SYK ) has outperformed the market over the past 20 years by 2.97% on an annualized basis producing an average annual return of 11.01%. Currently, Stryker has a market capitalization of $134.77 billion. Buying $1000 In SYK: If an … Full story available on Benzinga.com